Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Benef Microbes ; 12(3): 283-293, 2021 Jun 15.
Article in English | MEDLINE | ID: mdl-34030609

ABSTRACT

Escherichia coli Nissle (EcN), a probiotic bacterium protects against several disorders. Multiple reports have studied the pathways involved in cardiac hypertrophy. However, the effects of probiotic EcN against diabetes-induced cardiac hypertrophy remain to be understood. We administered five weeks old Wistar male (271±19.4 g body weight) streptozotocin-induced diabetic rats with 109 cfu of EcN via oral gavage every day for 24 days followed by subjecting the rats to echocardiography to analyse the cardiac parameters. Overexpressed interleukin (IL)-6 induced the MEK5/ERK5, JAK2/STAT3, and MAPK signalling cascades in streptozotocin-induced diabetic rats. Further, the upregulation of calcineurin, NFATc3, and p-GATA4 led to the elevation of hypertrophy markers, such as atrial and B-type natriuretic peptides. In contrast, diabetic rats supplemented with probiotic EcN exhibited significant downregulated IL-6. Moreover, the MEK5/ERK5 and JAK2/STAT3 cascades involved during eccentric hypertrophy and MAPK signalling, including phosphorylated MEK, ERK, JNK, and p-38, were significantly attenuated in diabetic rats after supplementation of EcN. Western blotting and immunofluorescence revealed the significant downregulation of NFATc3 and downstream mediators, thereby resulting in the impairment of cardiac hypertrophy. Taken together, the findings demonstrate that supplementing probiotic EcN has the potential to show cardioprotective effects by inhibiting diabetes-induced cardiomyopathies.


Subject(s)
Cardiomegaly/therapy , Diabetes Mellitus, Experimental/therapy , Diabetic Cardiomyopathies/therapy , Escherichia coli/physiology , Interleukin-6/antagonists & inhibitors , MAP Kinase Signaling System/drug effects , Probiotics/therapeutic use , Animals , Calcineurin/metabolism , Cardiomegaly/metabolism , Cardiomegaly/physiopathology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/physiopathology , Diabetic Cardiomyopathies/metabolism , Diabetic Cardiomyopathies/physiopathology , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Heart Ventricles/physiopathology , Interleukin-6/metabolism , Janus Kinase 2/metabolism , MAP Kinase Kinase 5/metabolism , Male , Mitogen-Activated Protein Kinase 7/metabolism , Rats , Rats, Wistar , STAT3 Transcription Factor/metabolism , Streptozocin
2.
Biotech Histochem ; 95(3): 163-170, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32053010

ABSTRACT

Diabetes is a metabolic disorder that damages many organs. We investigated the effects of reperfusion using lactate Ringer's solution (LR) in a diabetic animal model. Eight-week-old rats were divided into groups: control, hemorrhagic shock induced (HS), diabetes mellitus (DM), DM plus HS (DM + HS) and DM rats that received LR after HS (DM + HS + LR). HS was induced by withdrawing blood from the femoral artery and arterial pressure was maintained at 40 mm Hg for 1 h. Animals were perfused with either withdrawn blood or LR. Rats were sacrificed and hearts were collected from all groups. Histopathological studies were performed using left ventricles and western blotting analysis was performed using protein extracted from the left ventricle. Using the TUNEL assay, we found more apoptotic cells in the DM + HS group compared to the control group, whereas in animals resuscitated with LR, the number of apoptotic cells was reduced. Western blotting showed a significant reduction in apoptotic markers, cyt c, cas 9 and cas 3, and increased survival markers, pPI3K and pAKT, in the DM + HS + LR group. Reperfusion with LR may have therapeutic effects on trauma induced HS by blocking the IGF II R facilitated apoptosis pathway in diabetic rats.


Subject(s)
Receptor, IGF Type 2/drug effects , Reperfusion , Ringer's Lactate/pharmacology , Shock, Hemorrhagic/drug therapy , Animals , Apoptosis/drug effects , Diabetes Mellitus, Experimental , Disease Models, Animal , Rats , Shock, Hemorrhagic/metabolism
3.
Oncogene ; 36(14): 1978-1990, 2017 04 06.
Article in English | MEDLINE | ID: mdl-27748761

ABSTRACT

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Despite the availability of several treatment strategies, resistance to chemotherapeutic agents, which limits the effectiveness of anticancer drugs, is a major problem in cancer therapy. In this study, we used a histone deacetylases inhibitor (HDACi) to establish drug-resistant HCC cells and further analyzed the molecular mechanisms underlying the development of resistance in HCC cells. Compared with the parental cells, HDACi-resistant cells showed high metastatic and pro-survival abilities. Two-dimensional electrophoresis data showed that the cofilin-1 (CFL-1) protein was altered in HDACi-resistant cells and was highly expressed in resistant cells compared with parental cells. The molecular function of CFL-1 is actin depolymerization, and it is involved in tumor metastasis. In this study, we showed that CFL-1 inhibition decreased cell migration and increased cell apoptosis in HDACi-resistant cells. We observed that HDACi induced ROS accumulation in cells and apoptosis via promotion of the CFL-1 interaction with Bax and CFL-1 translocation to the mitochondria, resulting in cytochrome C release. Importantly, phosphorylation of CFL-1 by activated extracellular signal-regulated kinases 1 and 2 (ERK1/2) confers strong protection against HDAC inhibitor-induced cell injury. p-CFL-1 shows a loss of affinity with Bax and will not translocate to mitochondria, stably remaining in the cytoplasm. These results indicate that phosphorylation to inactivate CFL-1 decreased the chemosensitivity to HDAC inhibitors and resulting in drug resistance of HCC cells.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Cofilin 1/metabolism , Drug Resistance, Neoplasm , Histone Deacetylase Inhibitors/therapeutic use , Liver Neoplasms/drug therapy , Mitochondria/drug effects , Reactive Oxygen Species/toxicity , Animals , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Liver Neoplasms/metabolism , Mice , Mice, Nude , Mitochondria/metabolism , Phosphorylation , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Tumor Cells, Cultured
4.
Cell Death Differ ; 21(8): 1262-74, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24786827

ABSTRACT

Hypertension-induced cardiac hypertrophy and apoptosis are major characteristics of early-stage heart failure. Our previous studies found that the activation of insulin-like growth factor receptor II (IGF-IIR) signaling was critical for hypertensive angiotensin II (ANG II)-induced cardiomyocyte apoptosis. However, the detailed mechanism by which ANG II regulates IGF-IIR in heart cells remains elusive. In this study, we found that ANG II activated its downstream kinase JNK to increase IGF-IIR expression through the ANG II receptor angiotensin type 1 receptor. JNK activation subsequently led to sirtuin 1 (SIRT1) degradation via the proteasome, thus preventing SIRT1 from deacetylating heat-shock transcription factor 1 (HSF1). The resulting increase in the acetylation of HSF1 impaired its ability to bind to the IGF-IIR promoter region (nt -748 to -585). HSF1 protected cardiomyocytes by acting as a repressor of IGF-IIR gene expression, and ANG II diminished this HSF1-mediated repression through enhanced acetylation, thus activating the IGF-IIR apoptosis pathway. Taken together, these results suggest that HSF1 represses IGF-IIR gene expression to protect cardiomyocytes. ANG II activates JNK to degrade SIRT1, resulting in HSF1 acetylation, which induces IGF-IIR expression and eventually results in cardiac hypertrophy and apoptosis. HSF1 could be a valuable target for developing treatments for cardiac diseases in hypertensive patients.


Subject(s)
Angiotensin II/metabolism , DNA-Binding Proteins/antagonists & inhibitors , JNK Mitogen-Activated Protein Kinases/metabolism , Myocytes, Cardiac/metabolism , Receptor, IGF Type 2/metabolism , Sirtuin 1/metabolism , Transcription Factors/antagonists & inhibitors , Animals , Apoptosis/physiology , Female , Heat Shock Transcription Factors , Humans , Male , Myocytes, Cardiac/cytology , Rats , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...